Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell.
## Primary Indications
* Short-term treatment of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Prophylaxis of stress-related mucosal injury (off-label/institutional protocol dependent).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose 40 mg twice daily. Doses up to 240 mg daily have been used; adjust based on clinical response.
* **IV Bolus:** 40 mg over 2 minutes or 15 minutes.
## Pediatric Dosing
* **Erosive Esophagitis (5 years or older):**
* 15 kg to <40 kg: 20 mg once daily.
* 40 kg or greater: 40 mg once daily.
* *Note: Duration of use typically limited to 8 weeks in children.*
## Dose Adjustments
* **Hepatic Impairment:** No specific dose adjustment defined for mild-to-moderate impairment, but monitor LFTs. Some clinicians decrease frequency in severe impairment.
* **Renal Impairment:** No dosage adjustment necessary.
* **Geriatric:** No dosage adjustment required.
## Contraindications
* Hypersensitivity to pantoprazole or any component of the formulation.
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus, and bone fractures (hip, wrist, spine) with long-term/high-dose use.
## Key Drug Interactions
* **pH-Dependent Absorption:** May decrease absorption of ketoconazole, atazanavir, and mycophenolate mofetil.
* **Methotrexate:** Potential for increased methotrexate levels, particularly in high-dose therapy.
* **Warfarin:** Monitor INR/PT; potential for increased risk of bleeding.
* **Clopidogrel:** Theoretical concern regarding decreased antiplatelet efficacy (clinical significance is debated).
## Monitoring
* Monitor for signs of *C. difficile* (persistent watery stools).
* Monitor magnesium levels if on long-term therapy or concomitant diuretics.
* Periodic monitoring of B12 levels during prolonged therapy (>1 year).
* Assess need for ongoing PPI therapy periodically; de-prescribe if no longer indicated.
## Clinical Pearls
* **Administration:** Oral delayed-release tablets should be swallowed whole; do not crush or chew. IV administration is for short-term use when oral therapy is not possible.
* **Efficacy:** Maximal acid suppression occurs after several days of consistent dosing.
* **Safety:** PPIs do not provide immediate relief for acute heartburn.
* **Note:** Always consult institutional protocols for stress ulcer prophylaxis (SUP) criteria, as PPIs are often overused in low-risk hospitalized patients, increasing the risk of hospital-acquired pneumonia and *C. difficile*.
***
*Disclaimer: This information is for educational purposes only. Always verify drug dosages, indications, and contraindications against current clinical guidelines, institutional protocols, and official prescribing information (package inserts) before prescribing or administering medication.*
